Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Parkinson's Diseasechevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Biosimilars for RA chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Specialtieschevron_right
      • chevron_leftTopics
      • Cardiology
      • Diabetes
      • Endocrinology
      • Neurology
      • Cancer
      • Primary Care
      • Dermatology
      • Biologics
      • MAC Lung Disease
    • Submit A Question
    close

    J. Wouter Jukema, MD, PhD, FESC, FACC MC

    J. Wouter Jukema, MD, PhD, FESC, FACC MC

    Professor of Cardiology

    Netherlands Heart Foundation

    Chairman, Leiden Vascular Medicine

    Leiden University Medical Center (LUMC)

    Leiden, Netherlands


    Related Videos

    Since both PCSK9 outcome trials demonstrated impressive safety when LDL-C levels are lowered into ranges much lower than 70 mg/dL, what should be the approach of the interventional and medical cardiologist to achieving LDL-C levels in this range? Video

    Since both PCSK9 outcome trials demonstrated impressive safety when LDL-C levels are lowered into ranges much lower than 70 mg/dL, what should be the approach of the interventional and medical cardiologist to achieving LDL-C levels in this range?

    What has been your experience with respect to patient satisfaction, discontinuation rates and toleration of this injection-based approach to LDL-C management? Video

    What has been your experience with respect to patient satisfaction, discontinuation rates and toleration of this injection-based approach to LDL-C management?

    In light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study? Video

    In light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study?

    Although the AHA Guidelines emphasize CV risk and mortality reductions with statins, ODYSSEY Outcomes provides comparable evidence for alirocumab. How compelling is the evidence for PCSK9 inhibition as a mediator of CV risk and mortality reduction? Video

    Although the AHA Guidelines emphasize CV risk and mortality reductions with statins, ODYSSEY Outcomes provides comparable evidence for alirocumab. How compelling is the evidence for PCSK9 inhibition as a mediator of CV risk and mortality reduction?

    As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediated CV risk reduction. Where is your specific focus for using these agents in this population? Video

    As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediated CV risk reduction. Where is your specific focus for using these agents in this population?

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED